FDA/CDC

Medtronic recalls HawkOne directional atherectomy system


 

Medtronic has recalled 95,110 HawkOne Directional Atherectomy Systems because of the risk of the guidewire within the catheter moving downward or prolapsing during use, which may damage the tip of the catheter.

The U.S. Food and Drug Administration has identified this as a Class I recall, the most serious type, because of the potential for serious injury or death.

The HawkOne Directional Atherectomy system is used during procedures intended to remove blockage from peripheral arteries and improve blood flow.

If the guideline moves downward or prolapses during use, the “catheter tip may break off or separate, and this could lead to serious adverse events, including a tear along the inside wall of an artery (arterial dissection), a rupture or breakage of an artery (arterial rupture), decrease in blood flow to a part of the body because of a blocked artery (ischemia), and/or blood vessel complications that could require surgical repair and additional procedures to capture and remove the detached and/or migrated (embolized) tip,” the FDA says in a recall notice posted today on its website.

To date, there have been 55 injuries, no deaths, and 163 complaints reported for this device.

The recalled devices were distributed in the United States between Jan. 22, 2018 and Oct. 4, 2021. Product codes and lot numbers pertaining to the devices are listed on the FDA website.

Medtronic sent an urgent field safety notice to customers Dec. 6, 2021, requesting that they alert parties of the defect, review the instructions for use before using the device, and note the warnings and precautions listed in the letter.

Customers were also asked to complete the enclosed confirmation form and email to rs.cfqfca@medtronic.com.

Health care providers can report adverse reactions or quality problems they experience using these devices to the FDA’s MedWatch program.

A version of this article first appeared on Medscape.com.

Recommended Reading

High-bleeding-risk AF patients cut stroke risk with Amplatzer Amulet
Type 2 Diabetes ICYMI
CABG surpasses PCI for diabetics out to 7.5 years
Type 2 Diabetes ICYMI
Brilinta reduces MACE in THEMIS trial
Type 2 Diabetes ICYMI
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
Type 2 Diabetes ICYMI
Dapagliflozin’s CKD performance sends heart failure messages
Type 2 Diabetes ICYMI
PCI success vs. meds only in diabetes may depend on LDL-C control
Type 2 Diabetes ICYMI
Eyes on ESC ‘21: Hope for EMPEROR-Preserved, guidelines remade
Type 2 Diabetes ICYMI
SUGAR trial finds superior stent for those with diabetes and CAD
Type 2 Diabetes ICYMI
AHA 2021 puts scientific dialogue, health equity center stage
Type 2 Diabetes ICYMI
Similar 10-year survival after CABG, PCI in heavy calcification
Type 2 Diabetes ICYMI